| Dec'17 | Dec'16 | Dec'15 | ||||
|---|---|---|---|---|---|---|
Statement [line items] | ||||||
Net income from continuing operations | ||||||
7,703 | 6,698 | 7,028 | ||||
Reversal of non-cash items | ||||||
7,058 | 8,437 | 9,070 | ||||
Dividends received from associated companies | ||||||
987 | 899 | 432 | ||||
Interest received | ||||||
97 | 43 | 34 | ||||
Interest paid | ||||||
708 | 723 | 646 | ||||
Other financial receipts | ||||||
- | - | 714 | ||||
Other financial payments | ||||||
272 | 155 | 23 | ||||
Taxes paid | ||||||
1,611 | 2,111 | 2,454 | ||||
Cash flows before working capital and provision changes from continuing operations | ||||||
13,254 | 13,088 | 14,155 | ||||
Payments out of provisions and other net cash movements in non-current liabilities | ||||||
877 | 1,536 | 1,207 | ||||
Change in net current assets and other operating cash flow items | ||||||
244 | -77 | -863 | ||||
Cash flows from operating activities from continuing operations | ||||||
12,621 | 11,475 | 12,085 | ||||
Cash flows used in operating activities from discontinued operations | ||||||
- | - | -188 | ||||
Total cash flows from operating activities | ||||||
12,621 | 11,475 | 11,897 | ||||
Purchase of property, plant and equipment | ||||||
1,696 | 1,862 | 2,367 | ||||
Proceeds from sales of property, plant and equipment | ||||||
92 | 161 | 237 | ||||
Purchase of intangible assets | ||||||
1,050 | 1,017 | 1,138 | ||||
Proceeds from sales of intangible assets | ||||||
640 | 847 | 621 | ||||
Purchase of financial assets | ||||||
468 | 247 | 264 | ||||
Proceeds from sales of financial assets | ||||||
330 | 247 | 166 | ||||
Purchase of other non-current assets | ||||||
42 | 149 | 82 | ||||
Proceeds from sales of other non-current assets | ||||||
1 | - | 1 | ||||
Divestments of interests in associated companies | ||||||
29 | - | - | ||||
Acquisitions and divestments of businesses, net | ||||||
-784 | -765 | -16,507 | ||||
Purchase of marketable securities and commodities | ||||||
580 | 530 | 595 | ||||
Proceeds from sales of marketable securities and commodities | ||||||
549 | 622 | 262 | ||||
Cash flows used in investing activities from continuing operations | ||||||
-2,979 | -2,693 | -19,666 | ||||
Cash flows used in/from investing activities from discontinued operations | ||||||
-140 | -748 | 8,882 | ||||
Total cash flows used in/from investing activities | ||||||
-3,119 | -3,441 | -10,784 | ||||
Dividends paid to shareholders of Novartis AG | ||||||
6,495 | 6,475 | 6,643 | ||||
Acquisition of treasury shares | ||||||
5,490 | 1,109 | 6,071 | ||||
Proceeds from exercise options and other treasury share transactions | ||||||
252 | 214 | 1,581 | ||||
Proceeds from non-current financial debts | ||||||
4,933 | 1,935 | 4,596 | ||||
Repayment of non-current financial debts | ||||||
188 | 1,696 | 3,086 | ||||
Change in current financial debts | ||||||
-755 | 1,816 | 451 | ||||
Impact of change in ownership of consolidated entities | ||||||
0 | 6 | 0 | ||||
Dividends paid to non-controlling interests and other financing cash flows | ||||||
10 | 7 | -4 | ||||
Cash flows used in financing activities | ||||||
-7,733 | -5,314 | -9,176 | ||||
Effect of exchange rate changes on cash and cash equivalents | ||||||
84 | -387 | -286 | ||||
Net change in cash and cash equivalents | ||||||
1,853 | 2,333 | -8,349 | ||||